Evolus signed an exclusive US deal with IBSA for Profhilo, a bio-remodeling skin quality injectable. It is not FDA-approved yet. Here is what to know.
Evolus signed an exclusive US licensing and distribution deal with Swiss pharmaceutical company IBSA for Profhilo, a bio-remodeling hyaluronic acid injectable that targets skin quality rather than volume. Profhilo is not FDA-approved in the US; Evolus will run the regulatory development needed before any American launch.
Evolus, the aesthetics company behind the FDA-approved Jeuveau neurotoxin, announced on July 8, 2026 that it has entered an exclusive US licensing and distribution agreement with IBSA, a Swiss multinational pharmaceutical firm, to develop and commercialize Profhilo in the United States. The move pushes Evolus beyond toxins and traditional fillers into what the industry calls skin quality, a category built around hydration, elasticity, and smoothness rather than added volume.
Profhilo is a bio-remodeling injectable made from a unique hyaluronic acid formulation. It is a market leader in Europe and is sold in more than 70 countries, with 4.8 million treatments administered worldwide since its 2015 launch. Important for US readers: Profhilo is not FDA-approved and cannot be marketed or administered in the United States today. This partnership is the first step toward a possible future US approval, not a launch.
Under the agreement, Evolus receives exclusive US rights to Profhilo and takes responsibility for the development activities required for US regulatory approval, then commercialization if and when the product clears the FDA. IBSA, which developed Profhilo, remains the manufacturer.
The deal terms are notable. Evolus is paying no upfront fee. Instead the companies are using a transfer-price model designed to support gross margins consistent with Evolus long-term financial framework. Evolus said the agreement is not expected to affect its 2026 revenue or operating outlook, or its 2028 targets. Evolus CEO David Moatazedi called Profhilo a natural complement to the company portfolio, addressing a distinct and rapidly growing area of consumer demand. IBSA General Manager Salvatore Cincotti said Evolus has demonstrated a unique ability to build consumer-focused aesthetic brands and execute in the US market.
Skin quality injectables are a well-established category in Europe but remain early stage in the United States. Unlike conventional hyaluronic acid fillers, which are placed to restore volume or contour a specific feature, Profhilo is designed for superficial application to improve overall skin hydration, elasticity, and smoothness across a treatment area. In markets where it is approved, this is described as bio-remodeling.
For a company known primarily for Jeuveau, adding a skin quality product broadens the range of concerns Evolus can address and diversifies its portfolio beyond neurotoxins and standard fillers. For consumers, it signals that a product with a large international track record may eventually become available in the US, though the evidence that matters for an American launch is FDA review, which has not yet happened.
The single most important open question is regulatory. Profhilo is not FDA-approved, and neither Evolus nor IBSA has published a timeline for filing or approval. Injectable skin quality products can face a lengthy US clinical and regulatory path, so a US launch is not imminent and is not guaranteed. Until the FDA acts, any US clinic advertising Profhilo would be offering an unapproved product.
Readers weighing skin quality treatments should focus on options that are legally available and administered by a licensed, qualified provider. This is general information and not medical advice. Discuss your goals, candidacy, and the regulatory status of any injectable with a licensed clinician before making a decision.